Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor ASC40 for Acne

--To date, approximately 50% enrolled patients have completed 12-week treatment and all enrolled patients are expected to complete 12-week treatment by the end...

Related Keywords

Huashan ,Henan ,China ,Shaoxing ,Zhejiang ,United States ,Hong Kong ,Hangzhou ,Chinese ,America ,Leihong Xiang ,Jinzij Wu ,Physician Of Dermatological Department ,Fudan University ,Hong Kong Stock Exchange ,Institute Of Dermatology ,Drug Administration ,Dermatology Division Of Chinese Medical Doctor Association ,Ascletis Pharma Inc ,Ascletis Pharma ,Global Assessment ,Chief Physician ,Dermatological Department ,Huashan Hospital ,Executive Deputy Director ,Deputy Director ,Dermatology Division ,Chinese Medical Doctor Association ,Topical Clascoterone Cream ,Patients With Facial Acne ,Two Phase ,North America ,